Last updated: September 22, 2026
See How Rhythm360 Fits Your HF Workflow
As soon as a cardiology practice implants devices from more than one OEM, staff must log into separate, non-interoperable portals to retrieve patient data. This pattern creates unsustainable administrative burden, duplicated effort, and data silos that no single clinician can fully reconcile.
The clinical consequences are direct. Manual processes, unreliable transmission, and alert fatigue from non-actionable notifications obscure signals that matter, such as new-onset atrial fibrillation, ventricular tachycardia, device malfunction, and significant weight gain in HF patients. Those missed events carry financial consequences too, because without centralized tracking of billable events and compliant documentation, practices miss revenue and absorb denials on complex remote monitoring codes.
The evidence that passive monitoring alone is insufficient is now substantial. The 2026 Surducan et al. meta-analysis of 16 randomized controlled trials found a statistically significant mechanistic gradient across telemedicine modalities (p for interaction = 0.008): non-invasive telemonitoring alone did not reach statistical significance for mortality reduction (RR 0.93; p = 0.14), while structured remote patient management integrating multidisciplinary care teams, pre-defined alert thresholds, and systematic GDMT optimization reduced mortality (RR 0.79).
The 2026 Nieuwenhuys et al. study found that RPM implemented as a layer on top of existing care pathways increased HF nurse consultations significantly (15.3 vs. 5.3; P<.001) without offsetting reductions elsewhere, which highlights a workload risk that structured, integrated platforms are specifically designed to prevent.
A vendor-neutral, AI-powered platform that unifies data across all OEMs and enforces a structured clinical response pathway from signal to documented action addresses these compounding problems.
Genuine integration starts with clear technical architecture. HL7 is the older, message-based standard common in legacy hospital systems, typically transferring data in scheduled batches, while FHIR is the modern, API-based standard enabling real-time data exchange. Bidirectional sync keeps EHR and platform data aligned in real time, while one-way data flow leaves records stale and forces manual re-entry. Vendor-neutral architectures ingest data from all OEMs, while OEM-locked platforms keep the portal fragmentation problem in place.
Ingesting data from Medtronic, Boston Scientific, Abbott, and Biotronik into one dashboard is only the baseline. The finish line is a documented clinical action in the EHR in Epic, Cerner, Athenahealth, eClinicalWorks, or Greenway Health. A platform that stops at data aggregation without enforcing a response pathway does not deliver clinically meaningful integration.
The core capabilities a practice should require from any integrated HF management platform are:
Rhythm360 is built to this standard. It ingests data from all major OEMs into a single dashboard and syncs bidirectionally with Epic, Cerner, Athenahealth, eClinicalWorks, and Greenway Health via HL7. Its AI-powered data reliability achieves greater than 99.9% transmissibility through redundant data feeds, computer vision, and AI-powered extrapolation. Intelligent alerting includes optional 24/7/365 oversight by certified cardiac technicians, and an integrated communication hub via Twilio keeps outreach documented. Rhythm-CIED and HF/HTN RPM operate as distinct but integrated service lines.
See How Rhythm360 Unifies Your Device Data
Understanding why integration matters requires grounding in how heart failure is classified and treated. Per the 2021 Universal Definition and Classification of Heart Failure, heart failure is classified by LVEF into three phenotypes: HFrEF (symptomatic HF with LVEF ≤40%), HFmrEF (symptomatic HF with LVEF 41–49%), and HFpEF (symptomatic HF with LVEF ≥50%). Each phenotype has distinct monitoring priorities and treatment responses. The four GDMT pillars for HFrEF are ARNI/ACEi/ARB, beta blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor. The 2026 ESC heart failure guidelines recommend rapid initiation and uptitration of foundational medical therapy before discharge and during frequent follow-up visits in the first 6 weeks after a heart failure hospitalization, and note that initiation of FMT and planning for CRT implantation may be considered simultaneously in appropriate HFrEF patients.
Device-level signals from CardioMEMS and HeartLogic become clinically meaningful only when integrated into a workflow. HeartLogic combines S3/S1 heart sounds, thoracic impedance, activity level, night heart rate, and respiratory rate into a single index; a nominal threshold of 16 indicates elevated risk of an HF event within approximately 34 days with approximately 70% sensitivity. Without a structured response pathway, that signal remains an alert instead of a clinical action.
The 2026 Calvanese et al. review concludes that clinical benefit depends less on the monitoring technology itself and more on timely, structured clinical reactions to alerts. The platform provides the infrastructure that makes those reactions consistent, documented, and scalable.
If the clinical evidence makes the case for integration, the 2026 HFSA/AAHFN scientific statement makes the case for how to evaluate it. The 2026 HFSA/AAHFN scientific statement (PubMed 41605748) addresses integrated health technologies in heart failure, covering remote monitoring, implementation barriers, and the conditions under which technology-enabled care improves outcomes. The statement identifies challenges to widespread implementation of integrated health technologies, including disruptions to clinician workflow, lack of interoperability between systems, and the need for expanded reimbursement, alongside factors such as suboptimal patient engagement, disparities in digital literacy and access, data privacy concerns, and substantial start-up and maintenance costs.
Practice leaders evaluating an integrated HF management platform should ask vendors the following six questions, drawn directly from the statement's framework:
This sequence shows how an integrated platform converts a physiological signal into a documented clinical action:
The MANAGE-HF study found that alert-triggered early intervention led to medication augmentation, primarily increased diuretic doses, in 74% of cases. A post hoc analysis of the OPTILINK trial found that patients appropriately contacted following a remote monitoring alert had a significant reduction in the primary endpoint of cardiovascular death or first hospitalization (HR 0.61; 95% CI 0.39–0.95; P = 0.027). Rhythm360's AI-powered alert triage filters non-actionable noise and prioritizes clinically significant events, reducing critical alert response times by up to 80%.
A centralized HF management platform gives a practice population-level visibility into GDMT gaps, such as which patients with HFrEF are not on an ARNI, ACEi, or ARB, which are missing a beta blocker, which lack an MRA, and which have not started an SGLT2 inhibitor. That visibility enables protocol-driven outreach, where a nurse or pharmacist contacts the patient, documents the gap, and triggers a prescriber review, instead of waiting for the next scheduled visit to surface the deficiency.
As the Calvanese et al. review noted earlier, GDMT optimization should be prioritized when alerts occur without overt congestion. A platform that surfaces GDMT gaps alongside device alerts makes that prioritization feasible at scale.
Reimbursement-native platform design means the architecture aligns with the documentation requirements of each billable code. The relevant codes and their platform design implications are:
The 2026 CMS Advancing Care for Heart Disease MIPS Value Pathway (MVP ID G0055) maps directly to platform documentation capabilities. Key measures include CMS135v14 (MIPS Quality ID 005) for ACE inhibitor, ARB, or ARNI therapy for left ventricular systolic dysfunction; CMS144v14 (MIPS Quality ID 008) for beta-blocker therapy for left ventricular systolic dysfunction; and CMS90v15 (MIPS Quality ID 377) for functional status assessments for heart failure. All three are telehealth eligible. A platform with bidirectional EHR integration and structured documentation workflows supports the data capture these measures require without extra manual abstraction. Rhythm360's automated CPT capture and documentation infrastructure helps practices improve billing and revenue outcomes, with practices achieving up to a 300% increase in revenue capture.
Review Your RPM and CIED Billing With Rhythm360
Rhythm360's onboarding, including EHR integration, typically takes a few days to a few weeks, which fits comfortably within a 90-day implementation window. A structured sequence for a cardiology practice follows:
With the implementation sequence in mind, the key question becomes which platform can execute it reliably. Rhythm360 was built to the standard outlined earlier, and its vendor-neutral ingestion, bidirectional EHR integration, AI-powered data reliability, and integrated communication hub support the clinical and financial outcomes described in this guide.
University of Chicago Medicine reviewed more than 73,000 reports annually through Rhythm360 in calendar year 2025, averaging more than 18,000 reports per quarter. That scale translates into earlier interventions and more consistent documentation.
In heart failure management, “integrated” means that data from all device manufacturers, RPM sensors, and the EHR flows into a single platform and that clinical actions taken in response to that data are documented back in the EHR without manual re-entry. A platform that aggregates data but does not enforce a structured response pathway, including alert triage, protocol-driven outreach, and documented clinical action, does not deliver clinically meaningful integration. True integration is a workflow outcome where every signal becomes a documented clinical action.
Integration with Epic and Cerner (Oracle Health) uses HL7 messaging for real-time clinical events and FHIR APIs for structured data exchange. Bidirectional integration means the platform can read patient data from the EHR and write clinical actions, such as notes, orders, and medication changes, back into the patient record. Rhythm360 integrates bidirectionally with Epic, Cerner, Athenahealth, eClinicalWorks, and Greenway Health via HL7. Practices should confirm that any platform they evaluate supports true bidirectional sync, rather than one-way data export, and that the integration has been validated in their specific EHR environment.
RPM billing requires the platform to track specific thresholds. 99453 covers initial device setup and patient education. 99454 requires at least 16 days of biometric data transmission in a 30-day period. 99457 covers the first 20 cumulative minutes of interactive synchronous clinical time per calendar month, and 99458 covers each additional 20 minutes. CIED codes operate on different cycles: 93294 (pacemaker professional) and 93295 (ICD professional) follow a 90-day cycle, as does 93296 (pacemaker/ICD technical). 93297 covers implantable cardiovascular physiologic monitors such as CardioMEMS, and 93298 covers subcutaneous cardiac rhythm monitors and loop recorders. Both are device-specific codes billable once per 30 days and splittable into professional (-26) and technical (-TC) components or billed global. A reimbursement-native platform tracks all of these thresholds programmatically, suppresses billing when documentation requirements are not met, and generates compliant records that reduce denial rates.
The 2026 HFSA/AAHFN scientific statement (PubMed 41605748) addresses integrated health technologies in heart failure. As discussed earlier, it identifies workflow disruption, interoperability gaps, and reimbursement limitations as key barriers. It supports integrated platforms that combine data aggregation with structured clinical response pathways, multidisciplinary team workflows, and systematic GDMT optimization, and it frames implementation barriers as addressable through defined onboarding sequences and clear role assignments within the care team.
A structured 90-day implementation sequence covers six phases: EHR integration and environment configuration (days 1–14), device enrollment and OEM data feed activation (days 15–30), staff role assignment and alert rule configuration (days 31–45), protocol dissemination and communication hub activation (days 46–60), go-live and billing workflow validation (days 61–75), and performance review and optimization (days 76–90). Rhythm360's onboarding, including EHR integration, typically takes a few days to a few weeks, so practices can reach go-live well within the 90-day window. The critical success factors include defining escalation protocols before go-live, assigning clear staff roles for alert review and patient outreach, and validating CPT tracking against real patient data before the first billing cycle closes.
Fragmentation across OEM portals, EHRs, GDMT tracking, and RPM billing costs cardiology practices both clinical actions and revenue. Disconnected portals leave signals that may not become documented actions. Undocumented actions become billable events that may not become captured revenue, and those gaps compound across a patient population of hundreds or thousands.
Rhythm360 unifies CIED and HF/HTN data into one vendor-neutral, AI-powered platform so that every signal, from a HeartLogic threshold crossing to a weight gain trend to a missed GDMT pillar, becomes a documented clinical action. The platform aligns with the technical, clinical, and reimbursement standards that the 2026 evidence base and regulatory environment require, and practices can implement it through a defined sequence without disrupting existing workflows.
Talk With Rhythm360 About Your HF Program
